This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chu, J. W. Articles by Feldman, D. Search for Related Content PubMed PubMed Citation Articles by Chu, J. W. Articles by Feldman, D.

Successful Long-Term Treatment of Refractory Cushing’s Disease with High-Dose Mifepristone (RU 486)

Departments of Medicine (J.W.C., D.F.M., A.R.H., D.F.) and Psychiatry (J.B., A.S.), Stanford University School of Medicine, Stanford, California 94305

Address all correspondence and requests for reprints to: David Feldman, M.D., Division of Endocrinology, Room S-005, Stanford University School of Medicine, Stanford, California 94305-5103.

Abstract

An extremely ill patient, with Cushing’s syndrome caused by an ACTH-secreting pituitary macroadenoma, experienced complications of end-stage cardiomyopathy, profound psychosis, and multiple metabolic disturbances. Initially treated unsuccessfully by a combination of conventional surgical, medical, and radiotherapeutic approaches, he responded dramatically to high-dose long-term mifepristone therapy (up to 25 mg/kg·d). Treatment efficacy was confirmed by the normalization of all biochemical glucocorticoid-sensitive measurements, as well as by the significant reversal of the patient’s heart failure, the resolution of his psychotic depression, and the eventual unusual return of his adrenal axis to normal. His 18-month-long mifepristone treatment course was notable for development of severe hypokalemia that was attributed to excessive cortisol activation of the mineralocorticoid receptor, which responded to spironolactone administration. This case illustrates the efficacy of high-dose long-term treatment with mifepristone in refractory Cushing’s syndrome. The case also demonstrates the potential need for concomitant mineralocorticoid receptor blockade in mifepristone-treated Cushing’s disease, because cortisol levels may rise markedly, reflecting corticotroph disinhibition, to cause manifestations of mineralocorticoid excess.

This article has been cited by other articles:

				F Castinetti, M Fassnacht, S Johanssen, M Terzolo, P Bouchard, P Chanson, C Do Cao, I Morange, A Pico, S Ouzounian, et al. Merits and pitfalls of mifepristone in Cushing's syndrome Eur. J. Endocrinol., June 1, 2009; 160(6): 1003 - 1010. [Abstract] [Full Text] [PDF]

				F Castinetti, I Morange, P Jaquet, B Conte-Devolx, and T Brue Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease Eur. J. Endocrinol., January 1, 2008; 158(1): 91 - 99. [Abstract] [Full Text] [PDF]

				S. Johanssen and B. Allolio Mifepristone (RU 486) in Cushing's syndrome Eur. J. Endocrinol., November 1, 2007; 157(5): 561 - 569. [Abstract] [Full Text] [PDF]

				J. W. Findling and H. Raff Cushing's Syndrome: Important Issues in Diagnosis and Management J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3746 - 3753. [Abstract] [Full Text] [PDF]

				P. B. Jacobson, T. W. von Geldern, L. Ohman, M. Osterland, J. Wang, B. Zinker, D. Wilcox, P. T. Nguyen, A. Mika, S. Fung, et al. Hepatic Glucocorticoid Receptor Antagonism Is Sufficient to Reduce Elevated Hepatic Glucose Output and Improve Glucose Control in Animal Models of Type 2 Diabetes J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 191 - 200. [Abstract] [Full Text] [PDF]

				S. Wust, E. F. C. van Rossum, I. S. Federenko, J. W. Koper, R. Kumsta, and D. H. Hellhammer Common Polymorphisms in the Glucocorticoid Receptor Gene Are Associated with Adrenocortical Responses to Psychosocial Stress J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 565 - 573. [Abstract] [Full Text] [PDF]

				T. Raivio, J. J. Palvimo, S. Kannisto, R. Voutilainen, and O. A. Janne Transactivation Assay for Determination of Glucocorticoid Bioactivity in Human Serum J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3740 - 3744. [Abstract] [Full Text] [PDF]